Clinical validation of the "in silico" prediction of immunogenicity of a human recombinant therapeutic protein

Clinical Immunology

Volumn 124, Issue 1, 2007, Pages 26-32

  Koren, E ^a   De Groot, A S ^b,c   Jawa, V ^d   Beck, K D ^d   Boone, T ^d   Rivera, D ^b   Li, L ^d   Mytych, D ^d   Koscec, M ^d   Weeraratne, D ^d   Swanson, S ^d   Martin, W ^b  

^a SCIOS INC   (United States)

^b EpiVax Inc   (United States)

^c BROWN UNIVERSITY   (United States)

^d AMGEN INC   (United States)

Author keywords

Antibody response; HLA; Immunogenicity prediction; Immunoinformatics; T cell epitope

Indexed keywords

EPITOPE; FPX PROTEIN; HLA DR ANTIGEN; HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT; T LYMPHOCYTE ANTIGEN; UNCLASSIFIED DRUG;

ALLELE; AMINO ACID SEQUENCE; ANTIBODY RESPONSE; ARTICLE; CARBOXY TERMINAL SEQUENCE; COMPUTER MODEL; CONTROLLED STUDY; DRUG DOSE ESCALATION; EPITOPE MAPPING; FEMALE; HAPLOTYPE; HLA SYSTEM; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; MALE; MEMORY T LYMPHOCYTE; NORMAL HUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; T LYMPHOCYTE;

ADOLESCENT; ADULT; ALGORITHMS; ANTIBODY FORMATION; COMBINATORIAL CHEMISTRY TECHNIQUES; COMPUTATIONAL BIOLOGY; COMPUTER SIMULATION; DRUG EVALUATION, PRECLINICAL; EPITOPES, T-LYMPHOCYTE; FEMALE; HUMANS; IMMUNODOMINANT EPITOPES; MALE; MIDDLE AGED; MODELS, IMMUNOLOGICAL; MODELS, MOLECULAR; PREDICTIVE VALUE OF TESTS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 34249010944     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2007.03.544     Document Type: Article

References (30)

1. Rosenberg A.S. Immunogenicity of biological therapeutics: a hierarchy of concerns. Dev. Biol. (Basel) 112 (2003) 15-21
2. Casadevall N., Nataf J., Viron B., Kolta A., Kiladjian J.J., Martin-Dupont P., Papo T., Ugo V., Teyssandier I., Varet B., and Mayeux P. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N. Engl. J. Med. 346 (2002) 469-475
3. Swanson S.J., Ferbas J., Mayeux P., and Casadevall N. Evaluations of methods to detect and characterize antibodies against recombinant human erythropoietin. Nephron, Clin. Pract. 96 (2004) 88-95
4. Li J., Yang C., Xia Y., Bertino A., Glaspy J., Roberts M., and Kuter D.J. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 98 (2001) 3241-3248
5. Baert F., Noman M., Vermeire S., Van Assche G., D'Haens G., Carbonez A., and Rutgeerts P. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N. Engl. J. Med. 348 (2003) 601-608
6. Kuter D. Clinical Aspects of Anti-drug Antibodies (2006 (June 18-21)), AAPS National Biotechnology Conference, Boston, MA
7. Zubler R.H. Naive and memory B cells in T-cell-dependent and T-independent responses, Springer. Semin. Immunopathol. 23 (2001) 405-419
8. De Groot A.S., and Berzofsky J.A. From genome to vaccine - new immunoinformatics tools for vaccine design. Methods 34 (2004) 425-428
9. Bioinformatics in vaccine design. In: De Groot A.S., and Berzofsky J.A. (Eds). Methods vol. 34 (2004) 425-501
10. De Groot A.S., Sbai H., Saint-Aubin C., McMurry J.A., and Martin W. Immuno-informatics: mining genomes for vaccine components. Immunol. Cell Biol. 80 (2002) 255-269
11. Ahlers J.D., Takeshita T., Pendleton C.D., and Berzofsky J.A. Enhanced immunogenicity of HIV-1 vaccine construct by modification of the native peptide sequence. Proc. Natl. Acad. Sci. U. S. A. 30 (1997) 10856-10861
12. Klee L., and Zand R. Probable epitopes: relationships between myelin basic protein antigenic determinants and viral and bacterial proteins. Neuroinformatics 2 (2004) 59-70
13. De Groot A.S., Knopp P.M., and Martin W. De-immunization of therapeutic proteins by T-cell epitope modification. Dev. Biol. (Basel) 122 (2005) 171-194
14. Barbosa M.D., Vielmetter J., Chu S., Smith D.D., and Jacinto J. Clinical link between MHC Class II haplotype and interferon-beta (IFN-beta) immunogenicity. Clin. Immunol. 118 (2006) 42-50
15. Stickler M., Rochanayon N., Razo O.J., Mucha J., Gebel W., Faravashi N., Chin R., Holmes S., and Harding F.A. An in vitro human cell-based assay to rank the relative immunogenicity of proteins. Toxicol. Sci. 77 (2003) 280-289
16. Tangri S., Mothe B.R., Eisenbraun J., Sidney J., Southwood S., Briggs K., Zinckgraf J., Bilsel P., Newman M., Chesnut R., Licalsi C., and Sette A. Rationally engineered therapeutic proteins with reduced immunogenicity. J. Immunol. 174 (2005) 3187-3196
17. Oliner J., et al. Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell 6 (2004) 507-516
18. De Groot A.S., Jesdale B.M., Szu E., and Schafer J.R. An interactive web site providing MHC ligand predictions: application to HIV research. AIDS Res. Hum. Retroviruses 13 (1997) 539-541
19. Schafer J.A., Jesdale B.M., George J.A., Kouttab N.M., and De Groot A.S. Prediction of well-conserved HIV-1 ligands using a matrix-based algorithm EpiMatrix. Vaccine 16 (1998) 1880-1884
20. Southwood S., Sidney J., Kondo A., Guercio M., Appella E., Hoffman S., Kubo R., Chestnut R.W., Grey H.M., and Sette A. Several common HLA-DR types share largely overlapping peptide binding repertoires. J. Immunol. 160 (1998) 3363-3373
21. De Groot A.S., and Jesdale B.M. Several common HLA-DR types share largely overlapping peptide binding repertoires. AIDS Res. Hum. Retroviruses 13 (1997) 539-541
22. De Groot A.S., Bosma A., Chinai N., Frost J., Jessdale B.M., Gonzales A., Martin W., and Saint-Aubin C. From genome to vaccine: in silico predictions; ex vivo verification. Vaccine 19 (2001) 4385-4395
23. De Groot A.S., Jesdale B., Martin W., Saint-Aubin C., Sbai H., Bosma A., Lieberman J., Skowron G., Mansourati F., and Mayer K.H. Mapping cross-clade HIV-1 vaccine epitopes using a bioinformatics approach. Vaccine 21 (2003) 4486-4504
24. Swanson S.J., Ferbas J., et al. Evaluation of methods to detect and characterize antibodies against recombinant human erythropoietin. Nephron. Clin. Pract. 96 (2004) 88-95
25. Mason S., La S., Mytych D., Swanson S.J., and Ferbas J. Validation of the BIACORE 3000 platform for detection of antibodies against erythropoietic agents in human serum samples. Curr. Med. Res. Opin. 9 (2003) 651-659
26. Iwai L.K., Yoshida M., Sidney J., Shikanai-Yasuda M.A., Goldberg A.C., Juliano M.A., Hammer J., Juliano L., Sette A., Kalil J., Travassos L.R., and Cunha-Neto E. In silico prediction of peptides binding to multiple HLA-DR molecules accurately identifies immunodominant epitopes from gp43 of paracoccidioides brasiliensis frequently recognized in primary peripheral blood mononuclear cell responses from sensitized individuals. Mol. Med. 9 (2003) 209-219
27. Helms T., Boehm B.Q., Assad R.J., Trezza R.P., Lehmann P.V., and Tary-Lehmann M. Direct visualization of cytokine producing recall antigen specific CD4+ memory T cells in healthy individuals and HIV patients. J. Immunol. 164 (2000) 3723-3732
28. Panina-Bordignon P., Tan A., Termijtelen A., Demotz S., Corradin G., and Lanzavecchia A. Universally immunogenic T cell epitopes: promiscuous binding to human MHC Class II and promiscuous recognition by T cells. Eur. J. Immunol. 19 (1989) 2237-2242
29. Watts C. The exogenous pathway for antigen presentation on major histocompatibility complex Class II and CD1 molecules. Nat. Immunol. 5 (2004) 685-692
30. Rosenberg A.S., and Worobec A.S. A risk-based approach to immunogenicity concerns of therapeutic protein products. BioPharm Int. 34-44 Suppl 1 (2004) S20